ライフサイエンスコーパス: flu

1 romaticity indices (HOMA, NICS-XY, ACID, and FLU).

2 ioning with cyclophosphamide/fludarabine (Cy/Flu).

3 h FLU+5FC and 53.8% (95% CI 43.1-64.1%) with FLU.

4 diseases such as AIDS, viral hepatitis, and flu.

5 olated cells and in response to 10(-8) mol/L FLU.

6 at it was like to be stricken by the Spanish flu.

7 e single cycle candidate influenza vaccine S-FLU.

8 f critical disease and mortality compared to flu.

9 nizations, including those for pneumonia and flu.

10 inated or are exposed to friends who get the flu.

11 owed similar adsorption properties for NA or FLU.

12 ing mild infections like common colds or the flu.

13 tal relevant concentrations of 6 and 42 ng/L FLU.

14 ficantly suppressed by pre-treating HSC with Flu.

15 iated behavioral changes during the seasonal flu.

16 r FLU+5FC, and US $628 (95% CI $557-709) for FLU.

17 weeks of oral 5FC and FLU, 1 week of AmB and FLU, 1 week of AmB and 5FC, 2 weeks of AmB and FLU, or 2

18 atio of 2:1:1:1:1 to 2 weeks of oral 5FC and FLU, 1 week of AmB and FLU, 1 week of AmB and 5FC, 2 wee

19 ral FLU and 5FC, $1763 for 1 week of AmB and FLU, $1861 for 1 week of AmB and 5FC, $2125 for 2 weeks

20 CDAA diet with vehicles, and CDAA diet with Flu (5 mg/kg or 10 mg/kg) (n = 8 each) through gavage fo

21 lity rate was 35.1% (95% CI 28.9-41.7%) with FLU+5FC and 53.8% (95% CI 43.1-64.1%) with FLU.

22 FLU costs were derived from costs of FLU+5FC in ACTA, by subtracting 5FC drug and monitoring

23 The cost-effectiveness of FLU+5FC vs FLU alone was measured as the incremental cos

24 The effectiveness and costs of FLU+5FC were taken from ACTA, which included a costing a

25 (95% confidence interval [CI] $776-927) for FLU+5FC, and US $628 (95% CI $557-709) for FLU.

26 n and NPs were randomized to twice-daily EDS-FLU (93, 186, or 372 mug) or exhalation delivery system

27 min (12% and 50%, respectively) compared to FLU (94%).

28 The specificity for Flu A and B virus detection by all methods was >97%.

29 the ID Now assay, LIAT, and Xpert assay for Flu A virus detection (93.2%, 100%, and 100%, respective

30 while the ID Now virus detected 102 samples (Flu A virus, 69 samples; Flu B virus, 37 samples; dual F

31 assay detected Flu A/B virus in 107 samples (Flu A virus, 73 samples; Flu B virus, 36 samples; dual F

32 /201 [0.5%]), the LIAT detected 112 samples (Flu A virus, 74 samples; Flu B virus, 38 samples; invali

33 ), and the Xpert assay detected 112 samples (Flu A virus, 76 samples; Flu B virus, 36 samples; invali

34 -care test from the BD Veritor antigen test (Flu A virus, 79.5%; Flu B virus, 66.7%).

35 The Luminex Aries Flu A/B & RSV assay is a fully automated sample-to-answe

36 This study demonstrates that the Aries Flu A/B & RSV assay is a suitable method for rapid and a

37 The clinical performance of the Aries Flu A/B & RSV assay was prospectively evaluated in compa

38 nal clinical sensitivity values of the Aries Flu A/B & RSV assay were 98.1% for influenza A virus, 98

39 nd were all accurately detected by the Aries Flu A/B & RSV assay.

40 enza A&B test compared to those of the Xpert flu A/B assay.

41 Among the 201 specimens tested, the CDC Flu A/B PCR assay detected Flu A/B virus in 107 samples

42 CDC Flu A/B PCR was used as a reference method to evaluate t

43 s tested, the CDC Flu A/B PCR assay detected Flu A/B virus in 107 samples (Flu A virus, 73 samples; F

44 s, 73 samples; Flu B virus, 36 samples; dual Flu A/B virus positive, 2 samples), while the ID Now vir

45 s, 69 samples; Flu B virus, 37 samples; dual Flu A/B virus positive, 4 samples; invalid rate, 1/201 [

46 respiratory viruses, particularly influenza (Flu), a virus responsible for substantial worldwide morb

47 The effects of FLU, a pesticide that is reported to be safer than neoni

48 a net, which is different as compared to the flu-a framework formed by the nonfunctionalized tetrahed

49 aterials display a new type of the augmented flu-a net, which is different as compared to the flu-a f

50 ess, suggesting possible therapeutic role of Flu against NASH.

51 At the end of the double-blind period, EDS-FLU (all doses) significantly improved all 4 defining di

52 In vivo, Flu alleviated steatosis-induced HSC activation and hepa

53 The cost-effectiveness of FLU+5FC vs FLU alone was measured as the incremental cost-effective

54 er 500 mg tablet, the ICER of 5FC+FLU versus FLU alone was US $65 (95% CI $28-208) per life-year save

55 th 1 week of AmB and 5FC and 2 weeks of Oral FLU and 5FC are cost-effective treatments.

56 ostly and more effective and 2 weeks of oral FLU and 5FC was less costly and as effective.

57 ratio for 1 week of AmB and 5FC versus oral FLU and 5FC was US $208 (95% confidence interval $91-121

58 er patient were US $1442 for 2 weeks of oral FLU and 5FC, $1763 for 1 week of AmB and FLU, $1861 for

59 of the singlet oxygen ((1)O2)-overproducing flu and chlorina1 (ch1) mutants of Arabidopsis (Arabidop

60 ronmentally challenging times of the Spanish Flu and Great Depression.

61 The electrochemical performance of FLU and NF on the N-CQD@Co(3)O(4)/MWCNTs/GCE surface was

62 performance in simultaneous determination of FLU and NF with a linear range of 0.05-590 muM and 0.05-

63 We demonstrate that Flu and RV, another common respiratory virus, induce gly

64 determination of anticancer drug Flutamide (FLU) and antibiotic drug Nitrofurantoin (NF) was develop

65 apeutic options against the influenza virus (flu) and increasing challenges in drug resistance make t

66 del compounds, ibuprofen (IBU), fluorescein (FLU), and 4',6-diamidino-2-phenylindole (DAPI), was achi

67 actions of two fluoroquinolones, flumequine (FLU), and norfloxacin (NOR), with goethite (alpha-FeOOH)

68 of AmB and 5FC, $2125 for 2 weeks of AmB and FLU, and $2285 for 2 weeks of AmB and 5FC.

69 received conditioning with TBI 300 cGy, CY, FLU, and ATG.

70 ently greater for all adult ages during RSV, flu, and combined RSV-flu outbreak periods compared to n

71 that includes information about vaccination, flu, and face-to-face social networks.

72 She was initially suspected of having flu, and she completed a course of oseltamivir; however,

73 She was initially suspected of having flu, and she completed a course of oseltamivir; however,

74 Vaccination with NPs loaded with H1N1 Flu antigen, R848, and PUUC increased percentage of CD8+

75 Antibody responses against EBV and FLU antigens or HHV-6A/B gene products either not expres

76 FLU at higher doses resulted in similar learning impairm

77 bed corticosteroid, fludrocortisone acetate (FLU), at concentrations between 0.006 and 42 mug/L.

78 on (93.2%, 100%, and 100%, respectively) and Flu B virus detection (97.2%, 94.4%, and 91.7%, respecti

79 rus in 107 samples (Flu A virus, 73 samples; Flu B virus, 36 samples; dual Flu A/B virus positive, 2

80 tected 112 samples (Flu A virus, 76 samples; Flu B virus, 36 samples; invalid rate, 6/201 [3.0%]).

81 tected 102 samples (Flu A virus, 69 samples; Flu B virus, 37 samples; dual Flu A/B virus positive, 4

82 tected 112 samples (Flu A virus, 74 samples; Flu B virus, 38 samples; invalid rate, 11/201 [5.5%]), a

83 BD Veritor antigen test (Flu A virus, 79.5%; Flu B virus, 66.7%).

84 trend for increased TNF-alpha suppression by FLU between V0 and V6 (P = .07) were observed in patient

85 was measured as 2.03 cm(2) V(-1) s(-1) from Flu-BPBPT.

86 , Flu/busulfan (Bu)/alemtuzumab (n = 8), and Flu/Bu/antithymocyte globulin (n = 1).

87 rabine (Flu)/melphalan/alemtuzumab (n = 20), Flu/busulfan (Bu)/alemtuzumab (n = 8), and Flu/Bu/antith

88 such as nalidixic acid (NA) and flumequine (FLU), but also salicylic acid (SA), natural organic matt

89 lation delivery system with fluticasone (EDS-FLU) capable of high/deep drug deposition improves outco

90 ogenic survival when compared with PSMA- PC3 flu cells.

91 tigen and subsequent protection against H1N1 flu challenge in mice (8-week or 24-months).

92 Cy/Flu conditioning was the probable cause for grade 3-4 he

93 FLU costs were derived from costs of FLU+5FC in ACTA, by

94 to host cells) sequence available from NCBI flu database, and showed an overall correspondence and l

95 eeks during which at least 10% of RSV and/or flu diagnostic tests were positive.

96 The lower FLU doses decreased average olfactory learning by 74% (l

97 Disease outbreaks such as SARS, MERS, Swine Flu, Ebola, and COVID-19 (on-going) have caused sufferin

98 ified protein derivative, Tetanus toxoid, or flu/EBV/CMV viral mix) in LN, despite strong responses i

99 The addition of FLU enhanced engraftment 3-fold.

100 Antiserum in the 1918 flu epidemic, contaminated yellow fever vaccines in Worl

101 Influenza A and B viruses cause seasonal flu epidemics.

102 B viruses are the primary cause of seasonal flu epidemics.

103 a A virus, influenza B virus causes seasonal flu epidemics.

104 ressed when EXECUTER1 (EX1) is absent in the flu ex1 double mutant.

105 of ethyl methanesulfonate (EMS) mutagenized flu ex1 plants for suppressor mutants with a flu-like ph

106 In flu ex1 safe1, all (1)O(2)-induced responses, including

107 in mice bearing PSMA+ PC3 PIP and PSMA- PC3 flu flank xenografts at a 740-kBq dose and in mice beari

108 in mice bearing PSMA+ PC3 PIP and PSMA- PC3 flu flank xenografts.

109 nude mice bearing PSMA+ PC3 PIP or PSMA- PC3 flu flank xenografts.

110 mice bearing PSMA(+) PC3 PIP and PSMA(-) PC3 flu flank xenografts.

111 globulin (ATG) with or without fludarabine (FLU), followed by T-cell-depleted bone marrow or unmanip

112 ation with a reporter influenza virus (Color-flu) for multicolor analysis.

113 Our results show that a good flu forecasting model can benefit from the augmentation

114 nd limitations of augmenting an already good flu forecasting model with internet-based nowcasts.

115 indings suggest that further improvements to flu forecasting, particularly seasonal targets, will nee

116 The ability to produce timely and accurate flu forecasts in the United States can significantly imp

117 gned to reveal immune strategies against the flu has uncovered an Achilles' heel for influenza replic

118 y comparison, in 16 patients with influenza (flu) hospitalized for pneumonia with similar clinicopath

119 been used to control the spread of seasonal flu; however, the virus continues to evolve and escape f

120 PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human PC cells after (211)At- 6: treatment.

121 PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human prostate cancer cells after treatment with (12

122 cting beta-agonist versus 100 mug or less of FLU in at least 4 visits.

123 ate flu vaccine delivery platform to control flu in humans.

124 g fenbendazole (FBZ) and flunixin meglumine (FLU) in swine liver.

125 vation (FK506-binding protein 5 induction by FLU) increased in the PBMCs of patients with difficult-t

126 xposure of human myeloid DCs to IFN-alpha or Flu increases TLR7 expression, suggesting they may have

127 Employee absenteeism caused by flu infection costs hundreds of millions of dollars ever

128 vir (Laninamivir Octanoate Hydrate) to treat flu infection.

129 w indicators of aromaticity such as the PDI, FLU, ING, and INB were defined in our group.

130 ting the lower respiratory tract, and that S-FLU is a promising universal influenza vaccine candidate

131 Flu is caused by the influenza virus that, due to mutati

132 The addition of 5FC to FLU is cost-effective for cryptococcal meningitis treatm

133 and the cost-effectiveness of adding 5FC to FLU is uncertain.

134 Early diagnosis of influenza (Flu) is critical for patient management and infection co

135 rom the United States, we find that seasonal flu leaves a transient wake of heterosubtypic immunity t

136 oxiella burnetii Q fever presents with acute flu-like and pulmonary symptoms or can progress to chron

137 Q-fever is a flu-like illness caused by Coxiella burnetii (Cb), a hig

138 causes human Q fever, an acute debilitating flu-like illness that can also present as chronic endoca

139 disease that typically manifests as a severe flu-like illness.

140 orically presented in outbreaks, often has a flu-like onset, and results in inflammatory symptoms.

141 people each year are infected worldwide with flu-like pathogens including influenza.

142 flu ex1 plants for suppressor mutants with a flu-like phenotype.

143 transient post-DC infusion chills (38%) and flu-like symptoms (84%), dermatitis (64%), hepatitis (13

144 ine encephalitis virus (VEEV), which elicits flu-like symptoms and encephalitis in humans, with an es

145 The clinical picture is variable but flu-like symptoms are common with bilateral interstitial

146 r first patient is a 31-year-old man who had flu-like symptoms due to COVID-19 and later developed an

147 uine encephalitis virus (VEEV), which causes flu-like symptoms leading to neurological symptoms in up

148 nfection manifests as a febrile illness with flu-like symptoms, which can progress to encephalitis an

149 scontinued due mostly to musculoskeletal and flu-like symptoms.

150 ing fever, respiratory distress, nausea, and flu-like symptoms.

151 of abdominal distention, fevers, chills, and flu-like symptoms.

152 to-transmitted alphavirus that causes severe flu-like symptoms.

153 ), cytomegalovirus viremia (17.8% vs 24.2%), flu-like syndrome (11.6% vs 14.1%), polyoma (BK) viremia

154 ons, but there have been reports of possible flu-like syndrome.

155 SDR were more common with 3HP, and mostly flu-like.

156 veral aromaticity indices (NICS, ACID, HOMA, FLU, MCI).

157 underwent transplantation with RIC by using Flu/Melph and for PIDs by using bone marrow (n = 93) or

158 en with PIDs undergoing transplantation with Flu/Melph RIC from a matched donor source.

159 Ds using RIC with fludarabine and melphalan (Flu/Melph) and to study the effect of donor type and ste

160 ity conditioning (RIC) included fludarabine (Flu)/melphalan/alemtuzumab (n = 20), Flu/busulfan (Bu)/a

161 would allow for greater insight into FBZ and FLU metabolism.

162 However, many African settings treat with FLU monotherapy, and the cost-effectiveness of adding 5F

163 1 h induction of (1)O2 using the conditional flu mutant.

164 In the fluorescent (flu) mutant, its release causes seedling lethality and i

165 Flu Near You (FNY) is an online participatory syndromic

166 Here, we combined Flu Near You data with additional sources (Hong Kong hou

167 r influenza pandemics in humans (the Spanish flu of 1918 [H1N1], the Asian flu of 1957 [H2N2], the Ho

168 onsiderably smaller than that of the Spanish flu of 1918.

169 s (the Spanish flu of 1918 [H1N1], the Asian flu of 1957 [H2N2], the Hong Kong flu of 1968 [H3N2], an

170 the Asian flu of 1957 [H2N2], the Hong Kong flu of 1968 [H3N2], and the swine origin flu of 2009 [H1

171 ong flu of 1968 [H3N2], and the swine origin flu of 2009 [H1N1]) are all proposed to have been caused

172 We tested the effects of FLU on Apis cerana olfactory learning in larvae (lower d

173 randomly placed into groups: no drug (UNT), FLU or FBZ administered.

174 background variables current smoking, a cold/flu or pneumonia within the past two years, female sex,

175 RSV (OR, 8.5 [95% CI, 3.9-18.5]; AFE, 88%), Flu (OR, 8.3 [95% CI, 4.4-15.9]; AFE, 88%), PIV (OR, not

176 U, 1 week of AmB and 5FC, 2 weeks of AmB and FLU, or 2 weeks of AmB and 5FC in Malawi, Zambia, Camero

177 mes ranged from 1.04 to 1.38 during the RSV, flu, or combined RSV-flu outbreaks compared to the nonou

178 stein-Barr virus [EBV], and influenza virus [FLU]) or HHV-6A/B antigens.

179 adult ages during RSV, flu, and combined RSV-flu outbreak periods compared to nonoutbreak periods and

180 and used this information to define RSV and flu outbreak periods in the Maryland area.

181 n adults aged >=65 years during combined RSV-flu outbreak periods.

182 to 1.38 during the RSV, flu, or combined RSV-flu outbreaks compared to the nonoutbreak periods, with

183 provide near real-time regional estimates of flu outbreaks in the United States.

184 We examined relationships of RSV and flu outbreaks to occurrence of 4 advanced medical outcom

185 Both RSV and flu outbreaks were associated with surges in MAARI-relat

186 A 30% increase in IL-8 suppression by FLU (P = .04) and a trend for increased TNF-alpha suppre

187 d speed in modern history, rivaling the 1918 flu pandemic.

188 orldwide to combat the H1N1 influenza "swine flu" pandemic.

189 tory syncytial virus (RSV), influenza virus (Flu), parainfluenza virus (PIV), human metapneumovirus (

190 hic information, level of concerns about the flu, past experience with illnesses, and the type of beh

191 To elucidate the molecular role of mucins in flu pathogenesis, we constructed a synthetic glycocalyx

192 In particular, the use for flu patients should be paid careful attention because of

193 vaccination campaigns) and when they get the flu (personalized flu warnings) could have a large impac

194 This review supports RSV, Flu, PIV, HMPV, AdV, RV, and CoV as important causes of

195 r mortality and 2 weeks of oral flucanozole (FLU) plus 5FC was non-inferior.

196 Africa (ACTA) trial, 2 weeks of fluconazole (FLU) plus flucytosine (5FC) was as effective and less co

197 spective, we briefly discuss the validity of flu polymerase as a drug target and its inhibition throu

198 stellate cell line, HSC-T6, with or without Flu-pretreatment for 2 h.

199 number of symptoms, duration of symptoms, or FLU-PRO scores.

200 Our paper demonstrates that flu-produced (1)O(2) triggers an EX1-independent signali

201 EDS-FLU produces clinically and statistically significant im

202 earing human PSMA(+) PC3 PIP and PSMA(-) PC3 flu prostate cancer xenografts on the upper right and le

203 e at a higher risk for developing influenza (flu)- related complications.

204 In most patients (68%), those receiving EDS-FLU reported "much" or "very much" improvement.

205 sses relevant to drug metabolism for FBZ and FLU, respectively.

206 ), inclusive of three distinct eras (Spanish Flu, Roaring '20 s, and the Great Depression), we evalua

207 = 0.40) led to similar sorbed amounts of NA, FLU, SA, silicates or HA as compared to the stoichiometr

208 and precipitation as driving forces of this flu season and nearly unanimously identified a single ro

209 emic is not predicted well after the peak of flu season has passed.

210 samples of H3N2 influenza during the 2014-15 flu season in the U.S.

211 s the most tropical climate during a typical flu season in the U.S.

212 ced for higher vaccine efficacy and moderate flu season intensity.

213 er mutations are likely to occur in the next flu season using historical glycoprotein hemagglutinin s

214 Prior to each annual flu season, health authorities recommend three or four v

215 ed in the Northern Hemisphere just after the flu season, suggesting that pandemic timing may be predi

216 dult recipients who developed 161 RVI over 5 flu seasons (from 2013 to 2018).

217 dictions of the 2014-2015 and 2015-2016 U.S. flu seasons are often more accurate than the same predic

218 redictive performance using five consecutive flu seasons spanning from 2008 to 2013 and qualitatively

219 H3N2) and 2013-2014 (pandemic H1N1; H1N1pdm) flu seasons.

220 Flu-SEC represents an orthogonal tool to single-particle

221 Moreover, the Flu-SEC technique reports the ratio of EV-bound and free

222 Flu-SEC was validated using red blood cell derived EVs (

223 The resulting platform, Flu-SEC, demonstrates a linear response to concentration

224 The results show the quantitative power of Flu-SEC: a highly linear fluorescence response over a wi

225 RP-HPLC-DAD-FLU separation enabled us to identify 20 derivatives, in

226 ch of gene chip analysis, we discovered that Flu significantly affects metabolism in primary human pD

227 In particular, the resulting M-flu-SO(2) (M: Zr, Hf) materials display a new type of th

228 ctions, and development of isotype-switched, flu-specific antibody responses.

229 t with no detectable HAI-antibodies but high flu-specific IgG-antibody titers mounted rapid functiona

230 lglycol chitosan produced the most effective flu-specific immune response.

231 juvant generated significant improvements in flu-specific responses compared with unmodified liposome

232 -cell subsets because a larger proportion of flu-specific T cells has a regulatory cell phenotype in

233 Using a stochastic model fit to seasonal flu surveillance data from the United States, we find th

234 mework, initially proposed and validated for flu surveillance, to produce near real-time estimates of

235 We examined RSV and influenza (flu) surveillance data from the US National Respiratory

236 rologous SwIV H1N1 challenged pigs, clinical flu symptoms were absent, while the control pigs had fev

237 (TBI), cyclophosphamide, and fludarabine (Cy/Flu/TBI200).

238 Although Flu-TM and TIM express classical phenotypic memory marke

239 memory markers and are polyfunctional, only Flu-TM protects against a lethal viral challenge.

240 -specificity: protective (Influenza-induced, Flu-TM) and non-protective (peptide-induced, TIM) spleen

241 6) )] with more bulky groups gives rise to a flu topology with a new 8-c inorganic cluster.

242 decreased in HSC-T6 cultured with CM from PA-Flu-treated PRHs compared to those cultured with CM from

243 context is important for the development of flu treatments.

244 epidemic prediction web tools such as Google Flu Trends (GFT) to assist in risk communication and res

245 e in online search engine data (e.g., Google Flu Trends (GFT)) has received a considerable amount of

246 motivation behind the development of Google Flu Trends (GFT).

247 om electronic health records, and historical flu trends within each state, and (2) a network-based ap

248 and next generation (BioSense 2.0 and Google Flu Trends) data for situational awareness of influenza

249 dels, including the latest version of Google Flu Trends, even though it uses only low-quality search

250 including the recent rise and fall of Google Flu Trends.

251 archive of weekly ILI estimates from Google Flu Trends; ILIf: fully-observed ILI rates from ILINet;

252 ium-substituted stannene [Cp*(IXy)(H)2 RuSn(=Flu)Trip] (5) and stanna-imine [Cp*(IXy)(H)2 RuSn(kappa(

253 evaluated in PSMA(+) PC3 PIP and PSMA(-) PC3 flu tumor models and in the PSMA(+) luciferase-expressin

254 SMA-positive PC-3 PIP and PSMA-negative PC-3 flu tumor-bearing mice revealed that (86)Y- 4-6: had hig

255 times volume of less than 15 d for PSMA- PC3 flu tumors and all other treatment groups (P = 0.002 by

256 juvanted (1 dose) or nonadjuvanted (2 doses) FLU-v (A-FLU-v or NA-FLU-v) or adjuvanted or nonadjuvant

257 The differences between A-FLU-v and A-placebo in median fold increase at day 42 we

258 The difference between A-FLU-v and A-placebo in the median fold increase in secre

259 No differences were seen between NA-FLU-v and NA-placebo.

260 FLU-v is a broad-spectrum influenza vaccine that induces

261 Adjuvanted FLU-v is immunogenic and merits phase 3 development to e

262 (1 dose) or nonadjuvanted (2 doses) FLU-v (A-FLU-v or NA-FLU-v) or adjuvanted or nonadjuvanted placeb

263 nonadjuvanted (2 doses) FLU-v (A-FLU-v or NA-FLU-v) or adjuvanted or nonadjuvanted placebo (A-placebo

264 nt that improves protection of an intranasal flu vaccination by a mechanism that does not appear to r

265 Routine seasonal flu vaccination is encouraged in patients on ICIs.

266 logical (influenza) and the other is social (flu vaccination).

267 ial approach to improve cellular immunity in flu vaccination.

268 and efficacy in combination with influenza (flu) vaccination.

269 glutinin antibodies and seasonal inactivated flu vaccine (TIV) can elicit broadly protective antihema

270 $1 billion over 5 y has been proposed in the Flu Vaccine Act.

271 ty of a pig model for intranasal particulate flu vaccine delivery platform to control flu in humans.

272 ced cancer patients on ICIs who received the flu vaccine during three 3 consecutive seasons: 2014-201

273 The US Flu Vaccine Effectiveness Network enrolled subjects aged

274 It is unclear if the flu vaccine exacerbates immune events in patients treate

275 with a higher dose of a heterologous H5N1 S-FLU vaccine induced weaker BAL and stronger tracheobronc

276 at within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex

277 Although the existing flu vaccines elicit strong antigen-specific antibody res

278 Current flu vaccines have failed to provide cross-protection aga

279 good candidates for inclusion in "universal" flu vaccines.

280 Among 2763 Flu VE Network case patients, 1325 (48%) were infected w

281 The Flu VE Network enrolled ambulatory care patients aged >=

282 ance and US Influenza Vaccine Effectiveness (Flu VE) Network data to evaluate consequences of this cl

283 US $1.30 per 500 mg tablet, the ICER of 5FC+FLU versus FLU alone was US $65 (95% CI $28-208) per lif

284 oratory Improvement Amendments (CLIA)-waived Flu virus assays.

285 re rapid, point-of-care molecular assays for Flu virus detection.

286 tacoronaviruses spike S2, and the H1N1Ca2009 flu virus hemagglutinin.

287 VADR improves the speed with which non-flu virus submissions to GenBank can be checked and impr

288 tion of combination adjuvants, mirroring the flu-virus related innate signaling pathways, could elici

289 immunity that impedes the emergence of novel flu viruses.

290 escent proteins of different colours ('Color-flu' viruses) to facilitate the study of viral infection

291 gns) and when they get the flu (personalized flu warnings) could have a large impact on reducing the

292 The effectiveness of FLU was derived from cohorts of consecutively enrolled p

293 EDS-FLU was superior on both coprimary end points (P < .001

294 and V6 in IL-8 and TNF-alpha suppression by FLU were observed in patients with difficult-to-control

295 tinin signal sequence has been suppressed (S-FLU), when administered to pigs by aerosol can induce CD

296 a relatively new pesticide, flupyradifurone (FLU), which has been developed, in part, because it appe

297 OVID-19 and 24 nonhospitalized patients with flu with milder symptoms, IFN-lambda and type I IFN were

298 h 500 mug or more of fluticasone propionate (FLU) with or without a long-acting beta-agonist versus 1

299 vels, such as, or even higher than, those in flu Without SAFE1, grana margins (GMs) of chloroplast th

300 e Molecular Systems, Inc.), and Xpert Xpress Flu (Xpert; Cepheid) are rapid, point-of-care molecular